Potential of seaweed in reducing blood glucose of obese type 2 diabetes patients

Recruiting

Conditions: type 2 diabetes
type 2 diabetes mellitus
10012653

Registration Number: NL-OMON48790

Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 60

Inclusion Criteria

Patients with T2DM and BMI>25
- All adults; age * 18 years
- Diabetes based on criteria of ADA
- Informed consent

Exclusion Criteria

-Type 1 or monogenetic forms of diabetes.
- Thyroid disease
- Pregnancy
- Usage of corticosteroids
- Usage of blood coagulants
- History of heartfailure or recent myocardial infarction within 3 months
- Transplantation

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome is the difference between the mean blood glucose levels<br /><br>measured during the first week of usual diet and during the last 5 weeks of<br /><br>daily seaweed consumption. Effects of seaweed will be compared with the effect<br /><br>of placebo. Blood glucose will be monitored continuously by a device<br /><br>(Medtronic, Eindhoven) blinded for the participants. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Examine if Sargassum or Fucus supplementation results in bodyweight reduction<br /><br>and in improvement of risk factors for cardiovascular disease (CVD). Secondary<br /><br>outcomes are differences between week 1 and week 6 in terms of:<br /><br>* Body weight, Glucose, HbA1c, total daily insulin use,<br /><br>* Body weight, body mass index, waist-to-hip ratio, blood pressure, plasma<br /><br>lipids and peripheral blood phagocyte inflammatory activation status and<br /><br>ability to generate pro-angiogenic accessory cells from blood monocytes.</p><br>